| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2015: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2014: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2013: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Outline of Final Research Achievements |
To investigate the role of cancer stem cell marker CD44 variant 6 (CD44v6) in the development of distant metastasis in patients with epithelial ovarian cancer. The association between the expression of CD44v6 and distant metastasis was evaluated based on immunohistochemical analysis. Distant metastasis-free survival was compared between the CD44v6-high and -low groups. At the time of ovarian cancer diagnosis, distant metastasis occurred in 13 of 53 patients in the CD44v6-high group and 17 of 133 patients in the CD44v6-low group. The median metastasis-free survival after stage I-III ovarian cancer diagnosis was 19.5 months in the CD44v6-high group and 39.5 months in the CD44v6-low group. Multivariate analysis demonstrated that CD44v6 expression was an independent risk factor for distant metastatic recurrence. In conclusion, CD44v6 represents an important predictor of distant metastasis.
|
